Get the Stockscreener App
1.20
0.01%
0.000100
After Hours:
1.20
Plus Therapeutics Inc stock is traded at $1.20, with a volume of 68,774.
It is up +0.01% in the last 24 hours and down -3.23% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$1.1999
Open:
$1.2
24h Volume:
68,774
Relative Volume:
1.35
Market Cap:
$7.08M
Revenue:
-
Net Income/Loss:
$-12.89M
P/E Ratio:
-0.4743
EPS:
-2.53
Net Cash Flow:
$-11.95M
1W Performance:
-3.23%
1M Performance:
-3.23%
6M Performance:
-17.81%
1Y Performance:
-40.89%
1-Day Range:
$1.0918
$1.20
1-Week Range:
$1.0918
$1.30
52-Week Range:
$0.925
$2.6702
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
1.20 | 7.08M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
Plus Therapeutics appoints new Chief Development Officer By Investing.com - Investing.com Nigeria
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer - citybiz
Plus Therapeutics appoints new Chief Development Officer - Investing.com India
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer's Candidate, Zervimesine (CT1812) - The Manila Times
Can This Veteran Drug Developer Transform Plus Therapeutics' Clinical Pipeline? - StockTitan
Stromal Vascular Fraction Market Set to Grow Significantly, - GlobeNewswire
Plus Therapeutics, Inc. Appoints Michael Rosol as Chief Development Officer -February 20, 2025 at 07:30 am EST - Marketscreener.com
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program - GlobeNewswire
Plus Therapeutics secures $5.7 million for cancer trials - Investing.com India
Plus Therapeutics Secures $3.7M in Convertible Notes Deal - TipRanks
Plus Therapeutics Secures $3.7 Million in Private Placement Financing and $2.0 Million Advance from CPRIT for Clinical Development of CNS Cancer Treatments - Nasdaq
Plus Therapeutics Lands $5.7M Strategic Investment to Accelerate Cancer Treatment Breakthrough - StockTitan
Week Ahead (Aug.16-20): FATE, PSTV To Present Data, Will AXSM Get FDA Nod? - RTTNews
Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights - br.ADVFN.com
Plus Therapeutics (NASDAQ:PSTV) Shares Down 1.3% – Here’s Why - Defense World
CARsgen's First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T Trial Achieves sCR at Week 4 - Yahoo Finance
The CRISPR companies are not OK - STAT
Glioma Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight - EIN News
LD Micro 360 Companies Set to Present this Week - ACCESS Newswire
Elevar Therapeutics Presents Results from Post-Hoc Analysis of CARES-310 Study Evaluating the Impact of Viral and Non-Viral Etiology on Survival in Hepatocellular Carcinoma - Yahoo Finance
MiNK Therapeutics Targets Immune Reconstitution to Combat - GlobeNewswire
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI - Yahoo Finance UK
Leptomeningeal Metastases Pipeline Analysis, Clinical - openPR
Leptomeningeal Metastases Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Epidemiology, Medication, and Companies by DelveInsight - The Globe and Mail
Leptomeningeal Metastases Drugs Market 2034: EMA, PDMA, FDA - openPR
Eli Lilly acquires cancer program from Scorpion Therapeutics in $2.5B deal - STAT
Exclusive-Blackstone mulls $4 billion-plus sale of Liftoff, sources say - Yahoo Finance
Leptomeningeal Metastases Treatment Market 2034: EMA, PDMA, - openPR
Exclusive: Warburg Pincus explores $5 billion-plus sale of Modernizing Medicine, sources say - Reuters
Stevanato Group (NYSE:STVN) & Plus Therapeutics (NASDAQ:PSTV) Head to Head Review - Defense World
Are Broader Antibody Patents Possible in US Through Means-Plus-Function Claiming? - JD Supra
Simulations Plus (SLP) Fell due to Concerns Over the Funding Environment - Yahoo Finance
STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space - BioWorld Online
Viracta stock falls on strategic review (VIRX:NASDAQ) - Seeking Alpha
Sermonix and Henlius Dose First Chinese Patient in Phase 3 - GlobeNewswire
FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval - BioSpace
PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 - GlobeNewswire
Plus Therapeutics Reports Promising 88% Response Rate in Phase 1 Cancer Treatment Trial - StockTitan
PSTV stock touches 52-week low at $1.12 amid market challenges - Investing.com UK
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia - GlobeNewswire
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients - Yahoo Finance
Investors in Padlock Therapeutics sue Bristol Myers Squibb over ‘milestone’ payments - STAT
Candel Therapeutics Stock Surges Over 100%Here's Why - Yahoo Finance
Candel Therapeutics Announces CAN-2409 Achieved Primary - GlobeNewswire
IO-202 Plus Azacitidine Elicits Responses in HMA-Naive Chronic Myelomonocytic Leukemia - OncLive
Plus Therapeutics (NASDAQ:PSTV) Price Target Lowered to $19.00 at Ascendiant Capital Markets - Defense World
Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash - The Manila Times
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim - GlobeNewswire
Plus Therapeutics to Present Crucial Phase 1 Data for Novel Brain Cancer Treatment at Major Symposium - StockTitan
Plus Therapeutics Expands Strategic Agreement with Telix - GlobeNewswire
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Plus Therapeutics Inc Stock (PSTV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hawkins Richard J | Director |
Sep 12 '24 |
Buy |
1.35 |
6,285 |
8,512 |
11,188 |
| Petersen Greg | Director |
Sep 11 '24 |
Buy |
1.35 |
12,500 |
16,875 |
48,921 |
| Clowes Howard | Director |
Sep 11 '24 |
Buy |
1.34 |
5,000 |
6,681 |
26,497 |
| HEDRICK MARC H | Chief Executive Officer |
Sep 10 '24 |
Buy |
1.23 |
8,000 |
9,839 |
20,425 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Sep 10 '24 |
Buy |
1.27 |
4,098 |
5,204 |
9,815 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
May 08 '24 |
Buy |
2.04 |
4,902 |
10,000 |
5,717 |
| HEDRICK MARC H | Chief Executive Officer |
May 08 '24 |
Buy |
2.04 |
12,255 |
25,000 |
12,425 |
| Petersen Greg | Director |
May 08 '24 |
Buy |
2.04 |
12,255 |
25,000 |
36,421 |
| Clowes Howard | Director |
May 08 '24 |
Buy |
2.04 |
9,804 |
20,000 |
21,497 |
| Hawkins Richard J | Director |
May 08 '24 |
Buy |
2.04 |
4,902 |
10,000 |
4,903 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):